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Abstract 
Cisplatin occupies a crucial role in the treatment of various malignant tumours. However, its efficacy and 
applicability are heavily restricted by severe systemic toxicities and drug resistance. Our study exploits 
the active targeting of supramolecular metallacages to enhance the activity of cisplatin in cancer cells 
while reducing its toxicity. Thus, Pd2L4 cages (L = ligand) have been conjugated to four integrin ligands 
with different binding affinity and selectivity. Cage formation and encapsulation of cisplatin was proven 
by NMR spectroscopy. Upon encapsulation, cisplatin showed increased cytotoxicity in vitro, in 
melanoma A375 cells overexpressing αvβ3 integrins. Moreover, ex vivo studies in tissue slices indicated 
reduced toxicity towards healthy liver and kidney tissues for cage-encapsulated cisplatin. Analysis of 
metal content by ICP-MS demonstrated that encapsulated drug is less accumulated in these organs 
compared to the ‘free’ one. 
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Introduction 
Recently, supramolecular coordination complexes (SCCs) have attracted exploration in the fields of drug 
delivery, biomolecular recognition and imaging.1,2 Thus, the number of reports on the bioactivity of three-
dimensional SCCs with different shapes, including helicates,3 metallacages,4 cubes,5 prisms6 and 
capsules,7 and different compositions - (MnLm) where M is usually Fe(II), Pd(II), Pt(II), or half-sandwich 
organometallic clips based on Ru(II), Os(II), or Ir(III) and Rh(III), and L is the ligand of the coordination 
complex - has substantially increased. In this context, supramolecular metallacages offer several 
properties making them attractive candidates for future drug delivery systems.8 These discrete chemical 
entities, at variance with metal organic framework (MOFs), feature a secure cavity to host small drug 
molecules, while the ability to modify the ligand structure both pre- and post-self-assembly allows for 
fine tuning of the overall properties like solubility in aqueous environment.9 Despite these promising 
properties, the full potential of metallacages as drug delivery vehicles has not been explored so far.2 
In 2012, Crowley and co-workers reported on the encapsulation properties of the anticancer 
drug cisplatin within Pd2L4 cages (L = 2,6-bis(pyridine-3-ylethynyl)pyridine as the bidentate ligand), 
studied by NMR and X-ray diffraction.10 Platinum-based anticancer drugs are the mainstay of 
chemotherapy regimens in clinic. Nevertheless, the efficacy of cisplatin is badly affected by serious 
systemic toxicities and drug resistance, and its pharmacokinetics is still under consideration.11 
Therefore, cisplatin encapsulation in metallacages could enable a better delivery approach, 
minimizing the systemic toxicity of the drug while reducing its speciation. More recently, we explored 
similar cationic [Pd2L4]4+ systems and developed the exo-functionalization of the ligand scaffold to add 
different functionalities (e.g. fluorescent tags).12,13 Structural studies by 1H NMR ad X-ray diffraction were 
performed demonstrating encapsulation of cisplatin.14,15 Furthermore, the cytotoxicity of the [Pd2L4]4+ 
cages have been tested in vitro against a small panel of human cancer cells, showing scarce or 
moderate antiproliferative activities depending on the ligand scaffold.15 However, in order to achieve 
tumour selectivity, we envisaged the conjugation of the cages to cancer-cell-specific ligands – such as 
used in virus-like particles16 – as the best strategy. Thus, we recently reported the first example of 
bioconjugation of self-assembled Pd2L4 cages to a linear model peptide.17 
Here we extended our investigation to the bioconjugation of the cages to integrin binding 
ligands. Integrins have been extensively studied as drug targets, interacting with the extracellular matrix 
(ECM) and thereby regulating many cellular functions, such as proliferation, migration, and survival.18,19 
In mammals, there are eight RGD recognizing integrin subtypes among them αvβ3 and α5β1, expressed 
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in cancer tissue and promoting tumour metastasis.19 Over the years, numerous small peptidic or 
peptidomimetic molecules were designed and used to selectively address various integrin sub-types to 
treat different pathologies or for imaging.20-26 As an example, the cyclic pentapeptide cyclo(RGDfV)27 
and the related Cilengitide28 were found to be potent ligands for the integrins αvβ3, αvβ5, and α5β1.25,29  
It is worth mentioning that direct tethering of integrin binding peptides to cytotoxic platinum 
complexes have been also reported. For example, Lippard et al. explored the targeting ability of linear 
and cyclic RGD and Asn–Gly–Asp (NGR) integrin targeting ligands, and synthesized a Pt(IV) series 
comprising mono- and difunctionalized complexes, which improved the cisplatin anticancer activity, 
once the Pt(IV) compound is reduced to cisplatin in the intracellular environment.30 More recently, other 
Pt(II) and Pt(IV) complexes, functionalized with cyclic and multimeric RGD-containing peptides, have 
been described.31,32 Interestingly, conjugation of a photoactivatable Pt(IV) prodrug to a cyclic RGD-
containing peptide, led to increased phototoxicity in melanoma cancer cells overexpressing the αv3-
integrin receptor.32 However, these targeting approaches do not address the problem of metallodrug 
speciation until the target is reached, and, therefore, possibilities of cisplatin encapsulation into a 
targeted drug delivery vector are extremely appealing.  
Hence, we conjugated a Pd2L4 metallacage to four integrin ligands for subtype specific targeting 
of integrin αvβ3 (compounds 1-3)26,27,33 or α5β1 (compound 4),34 respectively (Figure 1).23,24,35,36 Cage 
formation and cisplatin encapsulation were studied by NMR spectroscopy. The conjugated cages were 
first studied for their integrin recognition properties using an ELISA assay. Afterwards, the three cages 
targeted to αvβ3 and encapsulating cisplatin were tested for their antiproliferative effects against two 
human cancer cell lines with different levels of integrin expression, namely the melanoma cell line A375 
overexpressing αvβ3, and the lung cancer cell line A549, deprived of this integrin. Moreover, the toxicity 
of a representative cage and of its encapsulated cisplatin was evaluated ex vivo in healthy tissues. 
Finally, the accumulation of cisplatin was also studied in tissues by Inductively Coupled Plasma Mass 
Spectrometry (ICP MS). 
 
Results and Discussion 
Initially, the ligand L0 featuring a carboxylic acid group in exo-position has been synthesised 
adapting a previously reported procedure,12 to increase the overall yield and including a protecting step 
of the carboxylic moiety (See Experimental for details). Thus, L0 was used for coupling to the amino-
functionalized integrin ligands 1-4 to form the cage precursors L1-L4 (Fig. 1). The products were 
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analysed by various methods, including NMR spectroscopy (Figures S1-S7, S10-S11, S13-S14, S16-
17, S19-S20, SI). Afterwards, the cages C0-C4 were formed by self-assembly upon addition of 2 eq. of 
the Pd2+ precursor (Pd(MeCN)4(BF4)2), as proven by 1H NMR (Fig. S8-S9 and S12, S15, S18, S21, SI), 
and remained stable in solution for at least 24 h. 
In Figure 2, the stepwise addition of Pd2+ precursor to ligand L4 enabled following the self-
assembly process leading to cage C4 formation by 1H NMR spectroscopy. In details, to the free 
bioconjugated ligand L4 (4.00 eq. Figure 2A), Pd(MeCN)4(BF4)2 was added in four portions (0.50 eq., 
Figure 2B-E). The adjacent protons of the metal binding site undergo a significant shift of about 1 ppm 
(a to a' and b to b') and also the two remaining protons of the pyridyl residue (e to e’ and f to f’) slightly 
shift after binding of the Pd2+ ions. The more distant protons (c and d, and the protons of the integrin 
ligand) do not show any remarkable shift with binding of the Pd2+ precursor to form the cage C4 (Figure 
2E). The full consumption of the free ligand after an addition of 2.00 eq. Pd(MeCN)4(BF4)2 clearly 
indicates a ratio of ligand to Pd of 2:1, which could be explained by the formation of cage C4 (Pd2L44). 
 
 
 
Figure 1. Synthesis of the bioconjugated ligands L1-L4 and of cages C0 and C1-C4 via metal-mediated 
self-assembly. (HATU = hexafluorophosphate azabenzotriazole tetramethyl uronium, HOBt = 
hydroxybenzotriazole). Compounds 1-4 are the integrin binding ligands for αvβ3 (1-3) and α5β1 (4). The 
integrin ligands were originally described in the following literature: 127,35, 224,33, 326, and 423,34. 
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Figure 2. Titration of ligand L4 with Pd(MeCN)4(BF4)2 and self-assembly process leading to formation 
of cage C4 followed by 1H NMR spectroscopy. A. Spectrum of the bioconjugated metal ligand L4 (4.00 
eq.) in DMSO-d6. Addition of the Pd(MeCN)4(BF4)2 (B. 0.50 eq.; C. 1.00 eq.; D. 1.50 eq.; E. 2.00 eq.; as 
a solution in DMSO-d6) results in the step-wise self-assembly of cage C4. 
 
The bioconjugated cages C1-C4 as well as their precursors L1-L4 were assessed for their integrin 
binding affinity and selectivity by an established ELISA-like solid-phase binding assay.25,37 Data are 
reported in Table 1 and show that C1-C3 αvβ3 and C4 α5β1 complexes feature strong binding, as 
expected from the original binding affinity of the parent ligands L1-L4,25 while the unsubstituted cage 
C0 exhibited no binding affinity at all. Compared to Cilengitide,28 the metallacages C1-C4 show higher 
selectivity for their target integrin with affinities in the low nanomolar range. The observation that 
multimerization is improving the binding affinity of ligands is well-known and often investigated,38,39 this 
was also found by us for RGD-containing ligands very early.40,41 The role of multimerization is especially 
important for integrins42 as multimeric integrin ligands might help to enter cells by endocytosis as it is 
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used by viruses such as foot and mouth disease43 and used for virul-like-particles.16 Within the group of 
αvβ3 active cages C1-C3, the nature of the integrin binding ligand has an influence on the discriminating 
selectivity towards the other integrins. Whereas the cyclic peptides in C1 and C3 show increased affinity 
for all integrins upon cage formation, the peptidomimetic C2 displays in addition an enhanced selectivity 
for its target integrin αvβ3. The peptidomimetic α5β1 targeting cage C4, as well as the precursor L4, 
show very high selectivity for the integrin α5β1. The activity of L4 for α5β1 was far below 1 nM and might 
additionally be attributed to any unspecific interaction between L4 and the integrin. 
 
Table 1. IC50 values of metallacages C0-C4 and their ligand precursors L1-L4 for binding to RGD-
recognizing integrin subtypes α5β1, αvβ3, αvβ5 and αvβ6. 
 IC50 [nM] [a] 
compound 51  v3  v5 v6 
C0 >10000 >10000 >10000 >10000 
C1 20±2 2.1±0.8 49 ± 6 159±18 
C2 1025±331 0.98±0.24 6580 ±911 644±66 
C3 193±62 0.38±0.01 24±6 13±2 
C4 1.77±0.15 >10000 >10000 2370±303 
L1 215±71 24±5 147±9 479±39 
L2 66±12 3.3 ±1.3 827±118 148±11 
L3 396±127 0.87±0.31 156±20 64±13 
L4 <1 >1000 >10000 1361±151 
Cilengitide[b] 14.9±3.1 0.61±0.06 8.4±2.1 2050±640 
[a] The reported IC50 values were calculated using a sigmoidal fit to 16 data points, obtained from two serial dilution rows, by using 
Origin software package. All IC50 values determined were referenced to the affinity of the internal standard and are presented as 
mean ± SD. [b] IC50 values of Cilengitide as previously reported.
25 
 
Previously reported results on unsubstituted Pd2L4 cages showed that they are able to 
encapsulate two molecules of cisplatin as determined by X-ray diffraction and NMR spectroscopy.10,15 
Thus, we also studied the cisplatin encapsulation properties of the protected cage Bz-C0 by 1H NMR 
(Fig. S22) and 1H DOSY NMR (Fig. S23-S27). The use of the protected cage instead of cage C0 is due 
to its higher solubility in the selected NMR conditions. In the 1H NMR spectrum in Fig. S22, the inward 
directed pyridyl proton signals undergo shifts upon encapsulation of 2 eq. of cisplatin, which are 
consistent with previously reported results.15 Specifically, Ha undergoes a downfield shift of Δδ = 0.0048 
ppm, and Hb of Δδ = 0.0148 ppm. Instead, for the benzyl proton He an upfield shift of Δδ = 0.114 ppm 
was observed (Fig. S22). Furthermore, the titration of cisplatin (up to 2 eq.) to a cage solution shows 
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marked differences in the 1H DOSY NMR spectra of free cisplatin, due to its encapsulation (Fig. S23-
S27). Further addition of cisplatin (3 eq.) shows reappearance of the free cisplatin signals (Fig. S27). 
Formation of the host-guest complex was also supported by 195Pt NMR spectroscopy where the 
disappearance of the classical Pt resonance of free cisplatin at -2080 ppm was observed upon addition 
of cage Bz-C0 (Figure S28). 
To validate our targeting concept, the antiproliferative effects of the coordination cages C1-C3, 
alone and encapsulating cisplatin [cisplatin(C1-3)] were evaluated against two different cell lines with 
different αvβ3 integrin expression pattern, in comparison to free cisplatin (see SI for experimental 
details). Specifically, the malignant melanoma cell line A375 has been shown to overexpress αvβ3,44 
while the human lung cancer cell line A549 is reported not to express it.45 The latter cell type is also 
resistant to cisplatin. Thus, cells were treated with increasing concentrations of cages and ligands; 
concentrations higher than 60 M were usually not reached due to the toxic effect induced by the 
presence of DMSO, particularly in the A375 cells. Drug encapsulation in each cage system was 
assessed by 1H NMR prior each experiment and confirmed encapsulation of 2 eq. of cisplatin per eq. of 
cage (data not shown). It should be mentioned that cisplatin stock solutions were freshly prepared in 
aqueous solution (1 mM) to avoid ligand exchange reactions with DMSO.  
The results are summarized in Table 2 and show that cages C1-C3 alone are scarcely toxic to 
the two cell lines, while cisplatin is moderately toxic only in the A375 cells (EC50 = 33.9 ± 2.9 M). 
Moreover, while treatment with cisplatin encapsulated in the “untargeted” cage C0 ([cisplatin⊂(C0)]) 
does not change the drug’s antiproliferative effects, cisplatin encapsulated in the bioconjugated cage 
C2 significantly increases its cytotoxic potency against the αvβ3 integrin expressing A375 cells (ca. 2-
fold more potent with respect to free cisplatin). Instead, the same [cisplatin⊂(C2)] formulation does not 
increase the cisplatin toxicity against the A549 cells with no expression of αvβ3. Concerning cages C1 
and C3, none of them increase significantly the cytotoxicity of cisplatin in the A375 cell line, which could 
be related to the lower selectivity against α5β1 and/or αvβ5 (Table 1). This result could also be due to 
differences in stability and drug release properties of the cages in the biological environment. Finally, it 
is worth mentioning that the Pd2+ precursor, as well as the different ligands L0 and L1-L4 were also 
studied and resulted to be non-toxic at the highest tested concentrations in both cell lines. 
Representative values are reported in Table 2 for L0. 
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Table 2. Antiproliferative activity (EC50 values) of different cages and cage:cisplatin (1:2) formulations 
in human A375 and A549 cancer cells compared to cisplatin after 24 h incubation. 
 
 EC50 [M] [a] 
Treatment A375 (melanoma) 
v3 ++  
A549 (lung) 
v3 – 
Ligand L0 > 50 > 100 
cage C0 > 50 82.6 ± 15.1[b] 
[cisplatin⊂(C0)] 31.5 ± 3.0 > 60 
cage C1 > 50 > 60 
[cisplatin⊂(C1)] 32.4 ± 1.2 > 60 
cage C2 > 50 > 60 
[cisplatin⊂(C2)] 15.80 ± 3.35* > 60 
cage C3 > 50 > 60 
[cisplatin⊂(C3)] 29.5 ± 0.6 > 60 
cisplatin 33.9 ± 2.9 63.2 ± 5.2 
[a] The reported EC50 values are presented as mean (± SEM) of at least four independent experiments.  
[b] Value taken from reference [12]. * (p  0.01) indicate the difference is significant when compared to samples 
treated with cisplatin only. 
 
In order to constitute an optimal drug delivery system, metallacages should be deprived of 
intrinsic toxic effects in normal tissues, and preferably reduce the toxicity exerted by the encapsulated 
drug. Thus, as proof of concept, cage C0, alone or encapsulating cisplatin, was tested for its toxicity on 
healthy rat kidney and liver tissues ex vivo using the precision-cut tissue slices (PCTS) technique.46-50 
PCTS are thin (150-250 μm) slices of viable tissue. In this model, all cells remain in their natural 
environment maintaining the original cell-cell and cell-matrix contacts, which are absent in classical 2D 
cell cultures in vitro. This method is a FDA-approved model for drug toxicity and metabolism studies, 
and is also useful to determine drug uptake/efflux mechanisms.46-50 Recently, we have successfully used 
the PCTS method to study the toxic effects of experimental anticancer organometallic compounds, 
including aminoferrocene-containing prodrugs, ruthenium-based kinase inhibitors, as well as gold(I) 
carbenes and gold(III) cyclometalated cytotoxic agents.46-50 
Thus, the viability of the liver and kidney slices was determined by incubating the PCTS with 
different concentrations of cage C0, alone or encapsulating cisplatin (cage:cisplatin = 1:2), for 24 h and 
measuring the ATP/protein content (see SI for details). Cisplatin was also administered in the same 
range of concentrations for comparison. The obtained results for liver and kidney are presented in Fig. 
3 (A and B). As expected, and in line with previous results,49 cisplatin alone causes a marked reduction 
of slice viability in both organs. Instead, cage C0 was substantially not toxic even at the highest tested 
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concentration in the liver slices. Ligand L0 and the Pd2+ precursor were also non-toxic above 100 M 
(data not shown). Of note, encapsulated cisplatin showed a significantly reduced toxicity in both liver 
and kidney slices compared to free cisplatin. 
 
 
Figure 3 – A and B: Viability of Precision Cut Tissue Slices (PCTS) from liver (A) and kidney (B), treated 
for 24 h with different concentrations of cisplatin (5, 10 and 25M), cage C0 (10, 30 and 50 M) and 
encapsulated cisplatin [cisplatin⊂(C0)] ([cage]/[cisplatin] = 5/10, 15/30, 25/50 M). C and D: Total metal 
content (Pd and Pt) determined by ICP-MS in PCTS of liver (C) and kidney (D) treated for 24 h with 
different concentrations of cisplatin, cage C0 and encapsulated cisplatin ([cisplatin⊂(C0)]). The error 
bars show the standard deviation of at least three independent experiments. For statistical analysis the 
Two Independent Sample t-Test was applied. * (p ≤ 0.01) indicates the difference is significant when 
compared to its control (treatment with cisplatin at the same concentration). 
 
In order to evaluate the relation between toxicity and intracellular metal accumulation, we 
determined the Pt and Pd content of tissue slices exposed to cisplatin alone or encapsulated in cage 
C0 by ICP-MS. Thus, PCTS were incubated for 24 h in the same conditions as for the ATP determination 
described above. In PCTS, the metal concentration increases in a concentration dependent manner 
(Fig. 3, C and D). Overall, as expected,51 the Pt content is higher in kidney (Fig. 3D) than in liver (Fig. 
3C). However, the accumulation of Pd is somewhat higher in the liver than in the kidney PCTS. 
Moreover, the results suggest that Pd accumulation is not influenced by cisplatin encapsulation. As it 
can be observed in Fig. 3C, in the case of liver slices, cisplatin encapsulated in cage C0 is markedly 
less accumulated than free cisplatin. Similar conclusions can be made for kidney samples although the 
differences are not as significant (Fig. 3D). Thus, the obtained results are another indirect evidence that 
cisplatin encapsulation in the metallacage is mostly preserved even in biological environment.  
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In the liver, the content of Pd and Pt in the [cisplatin⊂(C0)] treated slices is roughly in accordance with 
the predicted metal stoichiometry (Pd:Pt). However, in the kidney, the Pt content is higher than the Pd 
content, and this result should be further investigated. Possibly, Pd is partly excreted from the tissue 
over 24 h, while Pt is not (or less). Alternatively, a part of cisplatin may be released from the cage before 
uptake and enter the tissue more efficiently than in the liver. In this latter case the overall Pt content may 
be the result of accumulation of both encapsulated and free cisplatin. However, this latter explanation 
may be less likely in liver as such an effect is not seen in this organ. 
 
In conclusion, we herein present an integrin selective supramolecular drug delivery system for cisplatin 
based on the Pd2L4 metallacage scaffold. Encapsulation of cisplatin in the RGD-modified metallacage 
exhibits increased anticancer effects in vitro, and the metallacaged cisplatin itself has a decreased 
toxicity against healthy tissues ex vivo. The latter observation is explained on the basis of reduced 
platinum uptake in healthy tissues. Although further studies are necessary to fully characterize the 
properties of metallacages as drug delivery systems, including their stability in physiological conditions 
and drug release properties, toxicity of cages conjugated with integrin ligands in healthy tissue, as well 
as study of the effects in in vivo models, our work constitutes a first proof-of-concept of the possible use 
of supramolecular coordination complexes for directed drug delivery. 
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Experimental 
Synthesis 
Synthesis and analysis of ligand L0 
Ligand L0 has been synthesised adapting a previously reported procedure,12 to increase the overall 
yield and including a protecting step of the carboxylic moiety (Scheme S1). The starting compound 
benzyl 3,5-dibromobenzoate was synthesised according to a previously reported procedure by benzyl 
protection of 3,5-dibromobenzoic acid,52 and fully characterized by NMR (see supplementary 
information for details and Figures S1-S6). 
 
Synthesis of ligands 1-4  
In this section we report the general procedures (GPs) for the synthesis of the integrin binding ligands. 
For details and analysis, we refer to the supplementary material. 
GP1 Loading of TCP-resin. Peptide synthesis was carried out using 2-chlorotrityl chloride resin (2-CTC-
resin) (0.9 mmol/g) following standard Fmoc-strategy. Fmoc-Xaa-OH (1.20 eq.) were attached to the 
resin with DIPEA (2.50 eq.) in anhydrous CH2Cl2 (10 mL/g resin) for 2 h at r.t. Remaining 2-chlorotrityl 
chloride groups were capped by adding a mixture of MeOH, DIPEA (5:1; v/v; 1.0 mL/g resin) for 15 min. 
The resin was then filtered and washed with CH2Cl2 (5x) and N-methylpyrrolidon (NMP; 3x). The loading 
capacity was estimated to be 0.9 mmol/g (100 %). 
GP2 On-Resin Fmoc Deprotection. The resin-bound Fmoc peptide was treated with 20% (v/v) piperidine 
in NMP twice (1x10 min, 1x5 min) and subsequently washed with NMP (5x). 
GP3 Standard Amino Acid Coupling. A solution of Fmoc-Xaa-OH (2.00 eq.), O-(7-azabenzotriazol-1-yl)-
N,N,N’,N’-tetramethyluronium-hexafluorphosphate (HATU) (2.00 eq.), 1-hydroxybenzotriazole (HOBt; 
2.00 eq.), and DIPEA (5.00 eq.) in NMP (10 mL/g resin) was added to the resin-bound free amine 
peptide and shaken for 60 min at r.t. The resin was then washed with NMP (5x). 
GP4 Cleavage of Linear Peptides from the Resin. For complete cleavage from the resin, the peptides 
were treated with a solution of CH2Cl2 and hexafluoroisopropanol (HFIP; 4:1; v/v) for 15 min at r.t. (2x). 
The solvent was then evaporated under reduced pressure. 
GP5 Peptide cyclization. To a solution of linear peptide in DMF (2 mm peptide concentration) and 
NaHCO3 (5.00 eq.) diphenylphosphoryl azide (DPPA; 3.00 eq.) was added at r.t. and stirred until 
completion of cyclization was observed (monitored by HESI-MS, usually over night). The solvent was 
evaporated in vacuo and the crude material directly used for the next step. 
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GP6 Cbz-deprotection in solution. The Cbz-protected starting material was dissolved in MeOH (0.15 m), 
Pd on carbon (0.02 eq. 10 wt.%, dry) was added and hydrogen bubbled through the reaction mixture. 
Reaction progress was monitored by HESI-MS-analysis. After complete deprotection (usually 1-3 h) the 
reaction mixture was filtrated over Celite and the solid residue was washed with MeOH. The solvent 
was removed in vacuo. 
GP7 Coupling in Solution. The free amine was dissolved in DMF (~0.1 mol/L) and the acid (1.20 eq.), 
HATU (1.20 eq.), HOBt (1.20 eq.) and DIPEA (3.00 eq.) were added and the solution stirred over night 
or until no residual free amine could be observed (monitored by HESI-MS). After removal of the solvent 
in vacuo, the residue was taken up in EtOAc, washed with HClaq. (1 M, 2x) and brine. The organic phase 
was dried over Na2SO4, filtrated and the solvent removed in vacuo. The isolated products were purified 
via RP-HPLC or used as crude starting material for the next reaction step. 
GP8 Removal of acid-labile side-chain protecting groups: Cyclized peptides were stirred in a solution of 
TFA, CH2Cl2, water and TIPS (80-50:15-45:2.5:2.5; v/v/v) at r.t. until complete deprotection (approx. 1 h, 
monitored by HESI-MS). The reaction was quenched by addition of toluene and the solvent mixture was 
evaporated under reduced pressure (2x). 
GP9 On-resin N-methylation. The Fmoc-deprotected peptide was washed with CH2Cl2 (3x), a solution 
of 2-nitrobenzenesulfonylchloride (4.00 eq.) and 2,4,6-collidine (10.0 eq.) in CH2Cl2 was added and 
mixed for 20 min at r.t. The resin was washed with CH2Cl2 (3x) and THF abs. (5x). A solution containing 
PPh3 (5.00 eq.) and MeOH abs. (10.0 eq.) in THF abs. was added to the resin. DIAD (5.00 eq.) in a 
small amount THF abs. was added stepwise to the resin and mixed for 15 min at r.t. The resin was 
subsequently washed with THF (5x) and NMP (5x). For o-Ns deprotection, the resin-bound o-Ns-
peptides were stirred in a solution of mercaptoethanol (10.0 eq.) and DBU (5.00 eq.) in NMP (10 mL/g 
resin) for 5 min at r.t. The deprotection procedure was repeated once and the resin was subsequently 
washed with NMP (5x). 
GP10 Dde-deprotection in solution. The orthogonal deprotection of Dde was performed using a solution 
of hydrazine hydrate (2 vol.-%) in DMF for 30 min at r.t. The progress of the reaction was monitored by 
HESI-MS. After completion of the reaction, the solvent was removed under reduced pressure. 
GP11 Boc-, tBu-deprotection in solution. The starting material was dissolved in CH2Cl2 (~1 mL/100 mg) 
and an equal volume of TFA added at r.t. The solution was stirred for 30-60 min. The reaction was 
quenched by the addition of toluene and the solvent was evaporated under reduced pressure. The latter 
step was repeated once. 
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Synthesis of ligands L1-L4 
3,5-bis(pyridin-3-ylethynyl)benzoic acid (1.00 eq.), HATU (O-(7-azabenzotriazol-1-yl)-N,N,N’,N’-
tetramethyluronium-hexafluorophosphate, 1.00 eq.) and HOBt (1-hydroxybenzotriazole, 1.00 eq.) were 
dissolved in DMF (50 mM, referred to 1.00 eq.) and DIPEA (N,N-diisopropylethylamine, 2.00 eq.) was 
added. The solution was stirred at room temperature for 20 min and subsequently added to a solution 
of the corresponding amine (50 mM in DMF, 1.00 eq.) in DMF. The reaction mixture was stirred for 1 h 
at r.t., the solvent was removed in vacuo and the crude product was purified via semi-preparative RP-
HPLC. For details and analysis, we refer to the supplementary material. 
 
Synthesis of cage C0 
A solution of [Pd(NCCH3)4](BF4)2 (22.2 mg, 0.05 mmol, 2.00 equiv.) and ligand L0 (32.4 mg, 0.10 mmol, 
4.00 equiv.) in DMSO was stirred for 1 h at room temperature (Scheme S3). Following precipitation by 
addition of acetone and diethyl ether, the solid was then filtrated and washed with diethyl ether to yield 
the cage compound as an off-white solid (42.0 mg, 23.0 µmol, 92%). The product was characterized by 
NMR spectroscopy and high-resolution mass spectrometry (Figures S7-S9). 
 
Synthesis of cages C1-C4 
Synthesis of cages C1-C4 was achieved by self-assembly adapting the procedure reported for cage C0 
described above. The starting material (compounds L1-L4, ~2 µmol, 4.00 eq.) was weighed into an 
NMR-tube, respectively, and solubilized in DMSO-d6 (0.4 mL). A solution of Pd(MeCN)4(BF4)2 in DMSO-
d6 (20.54 mM, 2.00 eq.) was added to the solution in the NMR-tube and homogenized. In the 1H-NMR, 
the starting material was completely converted to the corresponding metallacage (C1-C4). For the 
ligands L1, L3 and L4 the molecular weight was calculated as one-fold TFA-salts, for ligand L2 a 
calculation without TFA-salt gave full consumption of the starting material. Due to their chromatographic 
instability, the formation procedure was optimized in NMR-solvent (DMSO-d6) and analyzed without 
isolating the product. Hereafter ELISA-assays were performed directly with these solutions. 1H-NMRs 
are shown in Figure 2 and Figures S10-S20 of the Supplementary Information. 
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Titration of Pd(MeCN)4(BF4)2 to a solution of ligand L4. 
The exclusively tetrameric cage formation of C4 (Pd2L44) is proven by a titration experiment. To a 
solution of ligand L4 (2.89 mg, 2.89 µmol, 4.00 eq.) in DMSO-d6 (0.4 mL) a solution of Pd(MeCN)4(BF4)2 
(14.3 mM) in DMSO-d6 was added in four portions (each 0.36 µmol, 23.8 µL). After each addition a 1H-
NMR spectrum was measured (see Figure 2). 
 
Encapsulation studies 
1H-NMR spectroscopy 
The benzoate protected Pd2L4 cage C0-Bz (8 mg, 36 µmol, 1.00 eq.) was dissolved in DMF-d7 (1mL) 
and the 1H-NMR (500 MHz, 64 scans) spectrum was recorded. Cisplatin (2 mg, 72 µmol, 2.00 eq.) was 
added and the yellow solution was stirred for 10 min. The 1H-NMR (500 MHz, 64 scans) spectrum of the 
sample was recorded and compared with the previous one (Figure S21). 
1H-DOSY NMR spectroscopy 
The benzoate protected ligand L0-Bz (15.7 mg, 37.9 µmol, 4.00 eq.) was dissolved in DMF-d7 (2.63 mL, 
14.4 mM) and a solution of Pd(MeCN)4(BF4)2 (8.41 mg, 18.9 µmol, 2.00 eq.) in DMF-d7 (461 µL, 
41.1 mM) was added and a 1H-NMR (400 MHz) spectrum was measured to ensure cage-formation. For 
each ratio, cisplatin was exactly measured out in a glass vial and the previously prepared cage solution 
was added to get a final cage:cis-Pt ration of 1:1, 1:2, 1:3. The solution was mixed for about 5 min to 
guarantee complete dissolution of cisplatin, subsequently a 1H-NMR and a DOSY-NMR was measured 
(Figure S22-S26). 
 
Integrin binding studies 
The affinity and selectivity of integrin ligands were determined by a solid-phase binding assay applying 
a previously described protocol37 that involves coated extracellular matrix (ECM) proteins and soluble 
integrins. The following compounds were used as internal standards: cilengitide29, c(f(NMe)VRGD) 
(αvβ3 – 0.54 nM, αvβ5 – 8 nM, α5β1 – 15.4 nM). Flat-bottomed 96-well ELISA plates (BRAND, 
Wertheim, Germany) were coated overnight at 4 °C with ECM protein (1) (100 μL per well) in carbonate 
buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6). Afterwards, each well was washed with PBS-T buffer 
(phosphate-buffered saline/Tween 20, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, 
0.01% Tween 20, pH 7.4; 3 × 200 μL) and blocked for 1 h at room temperature with TS-B buffer (Tris-
saline/bovine serum albumin (BSA) buffer, 20 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl2, 1 mM MgCl2, 
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1 mM MnCl2, pH 7.5, 1% BSA; 150 μL/well). Meanwhile, a dilution series of the compounds and internal 
standard was prepared in an extra plate, ranging from 20 μM to 256 pM in 1:5 dilution steps. After 
washing the assay plate three times with PBS-T (200 μL), 50 µL aliquots of the dilution series were 
transferred to each well from B-G in 6 appropriate concentrations. Well A was filled with 100 µL of TSB 
solution (blank), and well H was filled with 50 µl of TS-B buffer. Then, 50 µl of a solution of human 
integrin (2) in TS-B buffer was transferred to wells H–B and incubated for 1 h at r.t. The plate was 
washed three times with PBS-T buffer, and then primary antibody (3) (100 μL per well) was added to 
the plate. After incubation for 1 h at r.t., the plate was washed three times with PBS-T. Then, secondary 
peroxidase-conjugated antibody (4) (100 μL/well) was added to the plate and incubated for 1 h at r.t. 
Details on the respective solutions (1-4) for each integrin ligand are provided in the supplementary 
material. The plate was then washed three times with PBS-T, developed by the addition of SeramunBlau 
(50 μL/well, Seramun Diagnostic GmbH, Heidesee, Germany) and incubated for approx. 1 min at r.t. in 
the dark. The reaction was stopped with 3 M H2SO4 (50 μL/well), and the absorbance was measured at 
450 nm with a plate reader (infinite M200 Pro, TECAN).  The IC50 value of each compound resulted from 
a sigmoidal fit of two data rows (serial dilution rows) done by OriginPro 9.0G statistical software. All IC50 
values were referenced to the affinity of the internal standard. 
 
Antiproliferative assays 
Human malignant melanoma cancer cell line A375 and human lung cancer cell line A549 were obtained 
from ATCC and maintained in culture as described by the provider. The cells were cultured in DMEM 
(Dulbecco`s Modified Eagle Medium, Corning), supplemented with 10% fetal bovine serum (FBS, Eu-
approved South American Origin, Thermo Fisher Scientific) and 1% penicillin/ streptomycin (Gibco) at 
37 °C and 5% CO2. 
To monitor the self-assembly of the cages C0-C4 from ligands L0-L4 and to study the subsequent 
cisplatin encapsulation, 1H NMR studies were conducted directly in DMSO/H2O with a capillary of CDCl3 
(so the solution could then directly be used for further biological studies). Thus, each cage was dissolved 
in 1 mL of DMSO (max 20%) in H2O (stock solution 3 mM, 1 eq.) and added to a NMR tube containing 
a closed capillary of CDCl3. Only in the case of the poorly soluble cage C0 the initial stock solution 3 
mM was prepared in 100% DMSO. 1H NMR spectra were recorded before and after addition of 2 eq. of 
cisplatin to assess drug encapsulation. After confirmation of the encapsulation process, the solution was 
then extracted from the NMR tube and further diluted for the cell viability studies (0.1 to 60M) in DMEM 
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medium. The maximal tested DMSO concentration was 0.1%, except than in the case of the least soluble 
cage C0 (0.5%). In this latter case, control experiments with different concentration of DMSO were 
conducted to exclude possible effects on cells viability. Concentrations higher than 50M were not 
tested in A375 cells to avoid toxic effects of DMSO. Cisplatin (Sigma-Aldrich) was used as reference 
compound (tested between 0.1 to 100M), and its stock dilutions (1 mM) were freshly prepared in 
aqueous solution prior each experiment. For evaluation of cell growth inhibition, cells were seeded in 
96-well plates (Corning) at a concentration of 15000 cells/well and grown for 24 h in 200 μL complete 
medium. After 24 h incubation, 200 μL of the compounds’ dilutions were added to each well and the 
cells were incubated for additional 24 h. Afterwards, the medium was removed and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Fluorochem) in 10x PBS (Phosphate 
Buffered Saline, Corning) was added to the cells, at a final concentration of 0.3 mg/mL and incubated 
for 3-4 h. Then, the MTT solution was discarded and replaced with DMSO to allow the formed violet 
formazan crystals to dissolve. The optical density was quantified in quadruplicate at 550 nm using a 
multi-well plate reader. The percentage of surviving cells was calculated from the ratio of absorbance of 
treated to untreated cells. The EC50 value was calculated, using GraphPad Prism software, as the 
concentration causing 50% decrease in cell viability, using a nonlinear fitting of cell viability vs 
[treatment], and presented as mean ± SEM of at least three independent experiments. Statistical testing 
was performed using a Two Sample t-Test, to compare the [cisplatin⊂(C0-3)] treated samples with its 
control samples (treatment with cisplatin at the same concentration). A p-value of ≤0.01 was considered 
to be significant. 
 
Ex vivo studies 
Male Wistar rats (Charles River, France) of 250-300 g were housed under a 12 h dark/light cycle at 
constant humidity and temperature. Animals were permitted ad libitum access to tap water and standard 
lab chow. All experiments were approved by the committee for care and use of laboratory animals of 
the University of Groningen and were performed according to strict governmental and international 
guidelines. 
Livers and kidneys were harvested (from rats anesthetized with isoflurane) and immediately placed in 
University of Wisconsin solution (UW, Dupont Critical Care, Waukegan, IL, USA, 4⁰ C) until further use. 
For livers, cylindrical cores of 5 mm diameter were made using a Schlagbohrer Bosch (3 603 A 26 200). 
The kidneys, after removal of fat were cut in half lengthwise using a scalpel, and cores of 5 mm diameter 
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were cut from the kidney cortex from each half perpendicular to the cut surface using disposable Biopsy 
Punches (KAI medical, Japan). Precision-cut liver slices (PCLS, diameter 5 mm; thickness 250 μm; 
weight 5 mg;) and precision-cut kidney slices (PCKS, diameter 5 mm; thickness 150 μm; weight 3 mg;) 
were sliced with a Krumdieck tissue slicer (TSE, Bad Homburg, Germany) in ice-cold Krebs buffer at pH 
7.42, enriched with glucose to a final concentration of 25 mM and saturated with carbogen (95% O2/5% 
CO2).44 PCLS and PCKS were immediately moved to ice-cold UW and stored on ice until the beginning 
of the experiment for maximally 3 h. PCLS and PCKS were preincubated individually at 37 °C for 1 h in 
12-well plates in 1.3 mL of Williams Medium E (WME, Gibco by Life Technologies, UK) with glutamax-
1 (Gibco, Invitrogen, Paisley, Scotland) supplemented with 25 mM D-glucose, supplemented with 50 
μg/mL gentamycin (Gibco, Invitrogen, Paisley, Scotland) for PCLS and with ciprofloxacin HCl (10 µg/mL, 
Sigma-Aldrich, Steinheim, Germany) for PCKS. In the incubator (Sanyo CO2/O2 Incubator, 
PANASONIC, Secaucus, NJ, USA), the plates were under 80% O2 and 5% CO2 atmosphere, while 
being gently shaken (90 times/min). Preincubation allows the slices to restore the ATP levels44 and is 
helpful to remove debris and dead cells before the start of the experiments. After preincubation, the 
slices were moved to different well plates filled with 1.3 mL of prewarmed complete WME medium and 
different concentrations of the tested compounds and incubated for 24 h. The final concentrations of 
tested compounds are: Cage C0 = 5 μΜ, 15 μΜ and 25 μΜ with 0.83% DMSO v/v; cisplatin = 10 μΜ, 
30 μΜ and 50 μΜ; [cisplatin⊂(C0)] = [cisplatin]:[cage] of 5/10 μΜ, 15/30 μΜ and 25/50 μΜ with 0.83% 
DMSO v/v. For the final concentration of [cisplatin⊂(C0)]. Experiments were performed in triplicate using 
at least 3 individual rat organs. For each treatment, three slices were used to assess the ATP content. 
It is important to note that the PCLS and PCKS of each liver/kidney sample were exposed to all three 
compounds, as well as controls, in order to limit the influence of non-biological experimental variation. 
This experimental design helps to limit interindividual variation between compound’s classes, as well as 
between compounds and controls, in the data set.  
 
Evaluation of ATP content  
After PCTS pre-incubation, different concentrations of cisplatin and cage C0 or of encapsulated cisplatin 
[cisplatin⊂(C0)] were added to the wells and the slices were incubated for 24 h. Afterwards, slices were 
collected for ATP and protein determination, by snap freezing in 1 mL of ethanol (70% v/v) containing 2 
mM EDTA with pH = 10.9. After thawing, the slices were homogenized using a mini-bead beater and 
centrifuged. The supernatant was used for the ATP essay and the pellet was dissolved in 5 M NaOH for 
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the protein assay. ATP was measured using the ATP Bioluminescence Assay kit CLS II (Roche, 
Mannheim, Germany). The ATP content was corrected by the protein amount of each slice and 
expressed as pmol/μg protein. The protein content of the PCTS was determined by the Bio-Rad DC 
Protein Assay (Bio-Rad, Munich, Germany) using bovine serum albumin (BSA, Sigma-Aldrich, 
Steinheim, Germany) for the calibration curve.  
 
Statistics 
A minimum of three independent experiments were performed using slices in triplicates from each rat 
tissue. Statistical testing was performed with Two Sample t-Test to compare the [cisplatin⊂(C0)] treated 
samples with its control samples (treatment with cisplatin at the same concentration). A p-value of ≤0.01 
was considered to be significant.  
 
Metal content determination by ICP MS 
After incubation with the different concentrations of cisplatin, cage C0 or of the cage/cisplatin complex 
[cisplatin⊂(C0)], PCTS were washed with ice-cold Krebs-Henseleit buffer and snap-frozen and stored 
at -80°C until the analysis. 
 
Sample preparation and Pt and Pd determination 
The tissue samples were digested with 100 µL nitric acid overnight, all samples were completely 
dissolved. 100 µL hydrochloric acid and 800 µL milliQ were added to produce a volume of 1 mL. Prior 
to analysis the samples were diluted 20 times with 0.65% HNO3/0.1% HCl. 
The Pt and Pd contents were quantitated applying a Perkin Elmer (Waltham, MA, USA) Sciex Elan DRC-
e ICP-MS instrument, equipped with a Cetac ASX-110FR autosampler, a 0.2 mL min-1 MicroMist U-
series pneumatic concentric nebulizer (Glass Expansion, West Melbourne Vic, Australia) and a PC3 
cyclonic spray chamber (Elemental Scientific Inc., Omaha, NE, USA). ICP-MS RF power, lens voltage 
and nebulizer gas and flow were optimized on a daily basis and other settings were: 1 sweep/reading, 
25 readings/replicate, 5 replicates, 50 ms dwell time. The 195Pt+, 194Pt+ and 105Pd+ isotopes were 
monitored. Pt and Pd concentrations were determined by external calibration (0-20 ppb Pt and Pd). 
LODs were 0.1 µg L-1 for both Pt and Pd, (3*SD on blank, n=10) and the spike recovery were 102% and 
99% for Pt and Pd (n = 3), respectively. Pt and Pd single element PlasmaCAL standards (SCP Science, 
Quebéc, Canada) were used and the standards were prepared in a mixture of 0.1% HCl and 0.65% 
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sub-boiled HNO3 in MilliQ water. This mixture was furthermore used to dilute samples after digestion 
and as blank solution. 
 
Statistics 
A minimum of three independent experiments were performed using slices with triplicates for each 
condition. The PCLS and PCKS were prepared from three rats and in each experiment slices were 
exposed in triplicate. The Pt and Pd contents were expressed as nmol/mg slice and is presented as a 
mean (± SD) of at least three independent experiments. Pt and Pd concentrations were calculated to 
compare the [cisplatin⊂(C0)] treated samples with its control samples (treatment with cisplatin or C0 at 
the same concentration). 
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